Mymetics Corp (MYMX)

[Work Harder]

The three lipid formulations evaluated were cholesterol combined with either anionic (DOPG), neutral (DOPC), or cationic (DOTAP) unsaturated-lipids

https://dash.harvard.edu/handle/1/37799763

Influenza virosomes were prepared as follows. In short: per ml of final formulation, 8 mg of DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine; Merck, Darmstadt, Germany

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0163539

The incorporation of lipids and adjuvant into the virosomes was analyzed by thin-layer chromatography (TLC). The results of the TLC analysis confirmed that DOPC, DOPE and 3D-PHAD® were present in the virosome preparation (Fig. ?(Fig.3c).3c). To roughly quantify the amount of incorporated lipids and adjuvant, the intensities of the spots observed after TLC analysis of the virosomal lipids, shown in Fig. ?Fig.3c,3c, were determined using ImageJ analysis. The relative recoveries of DOPE and DOPC in the virosomes were essentially equal and represented approximately half of the amounts that were initially added, indicating a somewhat lower recovery than that of the viral protein (64%). However, the total quantity of virosome-associated adjuvant 3D-PHAD® was found to be less than 10% of the amount initially added. It therefore appeared that 3D-PHAD® was specifically lost during the production process.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061504/

and with synthetic 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC; Merck & Cie, Switzerland). The concentrated virosome intermediate mixture with the integrated PfCyRPA protein was obtained after removal of OEG on polystryrene beads (Bio-Beads; Bio-Rad, Switzerland) in a batch chromatography.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994490/